Neurology
Found 13 results
Filters: Keyword is Disease Progression  [Clear All Filters]
2020
Bagnato F, Gauthier SA, Laule C, Moore GRWayne, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA et al..  2020.  Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy.. J Neuroimaging. 30(3):251-266.
2019
Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA, Chiang GC.  2019.  Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.. AJR Am J Roentgenol. 212(4):883-891.
Roh DJ, Albers DJ, Magid-Bernstein J, Doyle K, Hod E, Eisenberger A, Murthy S, Witsch J, Park S, Agarwal S et al..  2019.  Low hemoglobin and hematoma expansion after intracerebral hemorrhage.. Neurology. 93(4):e372-e380.
Cabrera LY, Sarva H, Sidiropoulos C.  2019.  Perspectives on the Earlier Use of Deep Brain Stimulation for Parkinson Disease from a Qualitative Study of U.S. Clinicians.. World Neurosurg. 128:e16-e20.
2018
Mosconi L, Rahman A, Diaz I, Wu X, Scheyer O, Hristov HWebb, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RDiaz.  2018.  Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study.. PLoS One. 13(12):e0207885.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
2017
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K et al..  2017.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.. N Engl J Med. 376(3):221-234.
Mercuri MA, White H, Oliveira C.  2017.  Vision Loss and Symmetric Basal Ganglia Lesions in Leber Hereditary Optic Neuropathy.. J Neuroophthalmol. 37(4):411-413.
2016
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.
Chiang GC, Pinto S, Comunale JP, Gauthier SA.  2016.  Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.. J Neuroimaging. 26(3):289-95.
Zhang Y, Gauthier SA, Gupta A, Comunale J, Chiang GChia-Yi, Zhou D, Chen W, Giambrone AE, Zhu W, Wang Y.  2016.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM).. J Magn Reson Imaging. 44(2):426-32.
Murthy SB, Urday S, Beslow LA, Dawson J, Lees K, W Kimberly T, Iadecola C, Kamel H, Hanley DF, Sheth KN et al..  2016.  Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.. J Neurol Neurosurg Psychiatry. 87(11):1169-1173.